Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.24 -0.1%	$0.24	$0.17 ▼ $3.93	$765K	-0.09	130,945 shs	606 shs
CERO CERo Therapeutics	$9.55 -10.6%	$12.05	$6.71 ▼ $895.40	$3.73M	0.41	307,925 shs	247,102 shs
PBM Psyence Biomedical	$4.96 -2.9%	$4.55	$2.92 ▼ $699.19	$2.80M	0.15	112,860 shs	9,180 shs
ZVSA ZyVersa Therapeutics	$0.71 +4.9%	$0.62	$0.47 ▼ $6.30	$3.40M	0.74	1.56 million shs	450,549 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	-19.54%	+10.33%	-19.87%	-93.13%
CERO CERo Therapeutics	0.00%	-10.58%	+7.98%	-34.59%	-98.40%
PBM Psyence Biomedical	0.00%	+4.20%	+10.47%	+3.72%	-97.23%
ZVSA ZyVersa Therapeutics	0.00%	+10.28%	+9.94%	+13.08%	-81.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXI Avenue Therapeutics	2.5181 of 5 stars	0.0	4.0	4.6	2.2	0.0	1.9
CERO CERo Therapeutics	3.7391 of 5 stars	3.7	4.0	0.0	2.4	0.8	0.0
PBM Psyence Biomedical	1.6805 of 5 stars	0.0	5.0	0.0	2.7	1.7	0.6
ZVSA ZyVersa Therapeutics	1.0694 of 5 stars	0.0	5.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
CERO CERo Therapeutics	3.33	Buy	$45.00	371.20% Upside
PBM Psyence Biomedical	0.00	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATXI, ZVSA, PBM, and CERO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$220.00 ➝ $220.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
PBM Psyence Biomedical	N/A	N/A	$1.80 per share	2.75	$11.80 per share	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	$18.35	0.01	∞	N/A	N/A	-471.57%	-296.50%	8/7/2025 (Estimated)
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
PBM Psyence Biomedical	$1.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	8/8/2025 (Estimated)

Latest ATXI, ZVSA, PBM, and CERO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A
5/12/2025	Q1 2025	ZVSA ZyVersa Therapeutics	-$0.40	-$0.73	-$0.33	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
CERO CERo Therapeutics	N/A	0.73	0.73
PBM Psyence Biomedical	N/A	11.04	11.04
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
CERO CERo Therapeutics	29.64%
PBM Psyence Biomedical	77.44%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	1.80%
CERO CERo Therapeutics	12.72%
PBM Psyence Biomedical	3.60%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.18 million	2.02 million	Not Optionable
CERO CERo Therapeutics	8	390,000	337,000	N/A
PBM Psyence Biomedical	N/A	570,000	549,000	N/A
ZVSA ZyVersa Therapeutics	2	4.77 million	4.76 million	Not Optionable

ATXI, ZVSA, PBM, and CERO Headlines

Recent News About These Companies

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27 at 8:03 PM | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediatorâ„¢ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

June 26, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200

June 25, 2025 | quiverquant.comQ

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

June 25, 2025 | globenewswire.com

Zyversa Therapeutics Inc News (ZVSA) - Investing.com

June 25, 2025 | investing.com

ZVSA - ZyVersa Therapeutics Inc News - Morningstar

June 24, 2025 | morningstar.comM

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

May 22, 2025 | seekingalpha.com

ZyVersa Therapeutics Highlights New Research Supporting Inflammasome ASC Inhibitor IC 100 as Potential Treatment for Parkinson's Disease

May 20, 2025 | quiverquant.comQ

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases

May 20, 2025 | globenewswire.com

ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100

May 14, 2025 | nasdaq.com

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

May 12, 2025 | globenewswire.com

ZyVersa progresses with obesity inflammation treatment

May 9, 2025 | uk.investing.com

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

May 7, 2025 | globenewswire.com

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to ...

April 29, 2025 | msn.com

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

April 29, 2025 | globenewswire.com

ZyVersa Therapeutics CEO provides update on inflammasome ASC inhibitor IC 100

April 25, 2025 | markets.businessinsider.com

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status

April 24, 2025 | globenewswire.com

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental ...

April 10, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI, ZVSA, PBM, and CERO Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.24 0.00 (-0.08%)

As of 06/27/2025 03:47 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

CERo Therapeutics NASDAQ:CERO

$9.55 -1.13 (-10.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.57 +0.02 (+0.21%)

As of 04:12 AM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Psyence Biomedical NASDAQ:PBM

$4.96 -0.15 (-2.94%)

Closing price 06/27/2025 03:54 PM Eastern

Extended Trading

$16.70 +11.74 (+236.69%)

As of 04:00 AM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.71 +0.03 (+4.86%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.70 -0.01 (-1.32%)

As of 04:54 AM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time